Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Dynavax Technologies Corporation

     Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Dynavax
                           Technologies Corporation

PR Newswire

WAYNE, Pa., June 21, 2013

WAYNE, Pa., June 21, 2013 /PRNewswire/ --Ryan & Maniskas, LLP
(www.rmclasslaw.com/cases/dvax) announces that a class action lawsuit has been
filed in the United States District Court for the Northern District of
California on behalf of purchasers of Dynavax Technologies Corporation
("Dynavax" or the "Company") (NASDAQ: DVAX) common stock during the period
between April 26, 2012 and June 10, 2013 (the "Class Period").

(Logo: http://photos.prnewswire.com/prnh/20121112/MM11729LOGO )

For more information regarding this class action suit, please contact Ryan &
Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by
email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/dvax.

The complaint charges Dynavax and certain of its officers and directors with
violations of the Securities Exchange Act of 1934. Dynavax, a clinical-stage
biopharmaceutical company, discovers and develops products to prevent and
treat infectious and inflammatory diseases. Dynavax's lead product candidate
is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine designed to
provide higher and earlier protection with fewer doses than licensed vaccines.

The complaint alleges that throughout the Class Period, defendants violated
the federal securities laws by disseminating false and misleading statements
to the investing public about the viability of HEPLISAV. As a result of
defendants' false statements, Dynavax stock traded at artificially inflated
prices during the Class Period, reaching a high of $5.26 per share on May 2,

On April 26, 2012, Dynavax announced it had submitted a Biologics License
Application ("BLA") to the Food and Drug Administration ("FDA") for HEPLISAV,
seeking approval for the vaccine against all known subtypes of the hepatitis B
virus in adults ages 18 to 70. On November 15, 2012, Dynavax announced that
while the FDA's Vaccines and Related Biological Products Advisory Committee
had voted 13 to 1 that the data supported the efficacy of HEPLISAV, the
committee voted 8 to 5 that there was not sufficient data to adequately
support the safety of HEPLISAV. On this news, Dynavax stock fell $2.19 per
share to close at $2.44 per share on November 16, 2012. On February 25, 2013,
Dynavax announced that it received a Complete Response Letter ("CRL") from the
FDA regarding its BLA for HEPLISAV, which stated that, among other things,
HEPLISAV could not be approved for the full adult label of 18-70 years old
without additional safety data, though the FDA indicated a willingness to
consider approving the drug under a restricted-use label. Then, on June 10,
2013, Dynavax announced that it had recently conducted a follow-up meeting
with the FDA regarding its BLA license for HEPLISAV. According to the Company,
the FDA would require Dynavax to conduct additional safety trials before the
FDA would even consider approving HEPLISAV. On this news, Dynavax stock fell
another $1.07 per share to close at $1.40 per share on June 10, 2013, a
one-day decline of 43%.

If you are a member of the class, you may, no later than August 19, 2013,
request that the Court appoint you as lead plaintiff of the class. A lead
plaintiff is a representative party that acts on behalf of other class members
in directing the litigation. In order to be appointed lead plaintiff, the
Court must determine that the class member's claim is typical of the claims of
other class members, and that the class member will adequately represent the
class. Under certain circumstances, one or more class members may together
serve as "lead plaintiff." Your ability to share in any recovery is not,
however, affected by the decision whether or not to serve as a lead plaintiff.
You may retain Ryan & Maniskas, LLP or other counsel of your choice, to serve
as your counsel in this action.

For more information about the case or to participate online, please visit:
www.rmclasslaw.com/cases/dvax or contact Richard A. Maniskas, Esquire
toll-free at (877) 316-3218, or by e-mail at rmaniskas@rmclasslaw.com. For
more information about class action cases in general or to learn more about
Ryan & Maniskas, LLP, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan &
Maniskas, LLP is devoted to protecting the interests of individual and
institutional investors in shareholder actions in state and federal courts

CONTACT: Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old Eagle School Rd., Suite 311
Wayne, PA 19087

SOURCE Ryan & Maniskas, LLP

Website: http://www.rmclasslaw.com
Press spacebar to pause and continue. Press esc to stop.